Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma

[1] von der Maase H(2005)Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J clin oncol 23 4602-4608

[2] Sengelov L(2017)Pembrolizumab as second-line therapy for advanced urothelial carcinoma N Engl J Med 376 1015-1026

[3] Roberts JT(2017)Overall survival with combined nivolumab and ipilimumab in advanced melanoma N Engl J Med 377 1345-1356

[4] Bellmunt J(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135

[5] de Wit R(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-1639

[6] Vaughn DJ(2018)Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma N Engl J Med 378 1277-1290

[7] Wolchok JD(2015)Pseudoprogression and immune-related response in solid tumors J clin oncol 33 3541-3543

[8] Chiarion-Sileni V(2018)Patterns of response and progression to immunotherapy Am Soc Clinical Oncol educ book 38 169-178

[9] Gonzalez R(2017)iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics Lancet Oncol 18 e143-e152

[10] Brahmer J(2019)Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial Cancer 125 3208-3218

[1] von der Maase H(2005)Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J clin oncol 23 4602-4608

[2] Sengelov L(2017)Pembrolizumab as second-line therapy for advanced urothelial carcinoma N Engl J Med 376 1015-1026

[3] Roberts JT(2017)Overall survival with combined nivolumab and ipilimumab in advanced melanoma N Engl J Med 377 1345-1356

[4] Bellmunt J(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135

[5] de Wit R(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-1639

[6] Vaughn DJ(2018)Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma N Engl J Med 378 1277-1290

[7] Wolchok JD(2015)Pseudoprogression and immune-related response in solid tumors J clin oncol 33 3541-3543

[8] Chiarion-Sileni V(2018)Patterns of response and progression to immunotherapy Am Soc Clinical Oncol educ book 38 169-178

[9] Gonzalez R(2017)iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics Lancet Oncol 18 e143-e152

[10] Brahmer J(2019)Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial Cancer 125 3208-3218